Clinical Trial Update: A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) [Phase 2]

View source ↗

Summary

Phase 2 study of intratumoral CAVATAK in patients with stage IIIc/IV malignant melanoma has completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• CAVATAK

Snippet

Sponsor: Viralytics | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-15